

SMi Group Announce the Top 10 Reasons to Attend Superbugs & Superdrugs 2015

SMi's 17th annual Superbugs & Superdrugs conference takes place on the 25 – 26 March in London UK. Book by the 30th January for the £100 early bird discount.

LONDON, ENGLAND, UNITED KINGDOM, January 21, 2015
/EINPresswire.com/ -- Delivered by the SMi Group in collaboration with an esteemed speaker panel from industry experts such as BARDA, European Investment Bank, Redx Anti-Infectives, European Commission, Debiopharm, Absynth Biologics and GSK, the Superbugs & Superdrugs conference returns on the 25th - 26th March to Central London for its 17th annual instalment.



Top 10 reasons to <u>attend</u>:

- EXPERTISE: Expanding horizons on the growing global threat of anti-microbial resistance for almost two decades, Superbugs & Superdrugs will once again play host to a global audience of scientific leaders, academia, funding bodies and drug discovery specialists, providing a focal point to discuss clinical advancements, research and funding opportunities.
- HEAR FROM THE EXPERT SPEAKER LINE-UP: The packed agenda will feature 20 presentations including keynotes from BARDA, EFPIA, Redx Anti-Invectives and the European Investment Bank (EIB)
- HEAR CASE STUDIES: Hear an array of case study led addresses from industry experts such as GSK, Absynth Biologics, Achaogen Inc, Debiopharm International plus many more.

- ENGAGE IN 14 HOURS OF CONTENT: Immerse into new insights on key topics such as effective industry incentives, the use of new technologies, multi-resistant bacterial strains and antibiotic alternatives.
- JOIN THE DEBATE: Discuss how to de-risk and optimise clinical development of antimicrobials in a panel debate led by the conference chairman, Richard Bax. With over 36 years of industry experience, Richard is a key TranScrip expert in Infectious Diseases and has developed many antibiotics and antivirals. Richard will also host a roundtable on: How to best ensure a reliable pipeline of appropriate drugs.
- WELLCOME TRUST FUNDING OPPORTUNITIES: Introducing Wellcome Trust innovations, Senior Business Analyst, Timothy Jinks, will provide success stories on innovative therapeutics and explain the investment selection criteria.
- BENEFIT FROM TWO INTERACTIVE WORKSHOPS: Workshop A, entitled: Vision for the Future Designing Antimicrobials to Meet Future Needs, will provide strategic advice on target selection and lead optimisation. Workshop B, entitled Technical Aspects of Licensing an Antibiotic, will cover all the key scientific drivers and issues that need to be considered for an outward licence or in evaluating inward licensing opportunities.
- EXPAND KNOWLEDGE: Despite the enormous efforts in industry research for discovering broad spectrum antibacterials with new mechanisms of action, the newest molecule mechanism of action is 50 years old. ABAC Chief Scientific Officer, Domingo Gargallo-Viola to answer questions such as: What can we do to provide solutions and what have we learnt?
- NETWORK: Ample opportunity for discussion, including 2 morning coffee breaks, 2 networking lunches and 2 afternoon tea sessions. Make new contacts, meet old friends and form the relationships you can count on in the future.
- EARLY BIRD: Register now and benefit from the £100 early bird discount at http://www.smi-online.co.uk/goto/2015superdrugssuperbugs56.asp

Contact Fateja Begum on +44 (0)20 7827	6148 or email: fbegum@smi-online.co.uk
END	-

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the worlds most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Teri Arri SMi Group Ltd +44 (0) 20 7827 6162 email us here

This press release can be viewed online at: https://www.einpresswire.com/article/245544111

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2024 Newsmatics Inc. All Right Reserved.